Humana Inc. (HUM)

FairStock Score: 39/100 — MIXED

Key Financials

Strengths

• Large, diversified insurance platform with 67,060 employees and established market position in Medicare Advantage
• Low beta (0.41) provides defensive characteristics during market volatility
• Moderate debt levels (D/E 0.75) provide some financial flexibility
• Integrated CenterWell segment offers ancillary revenue streams beyond pure insurance
• Reported $1.3B in free cash flow despite operational challenges

Concerns

• Q4 2025 net loss of $796M with -2.45% margins indicates severe operational deterioration in core business
• Piotroski F-Score of 2/9 signals critically weak financial quality and deteriorating fundamentals
• Altman Z-Score of 1.91 places company in financial distress warning zone
• Medical cost inflation outpacing pricing power in Medicare Advantage segment threatens future profitability
• Negative FCF yield (-8.6%) indicates shareholder value destruction despite nominal cash generation

AI Analysis

Humana presents a classic value trap masquerading as a bargain. At 17.27x earnings with a market cap of $21.5B, the valuation appears reasonable on the surface. However, the fundamentals reveal significant deterioration that demands scrutiny. The company reported a staggering $796M net loss in Q4 2025, generating negative margins of -2.45%. This isn't merely a quarterly blip—it signals structural challenges in their core Medicare Advantage business, likely driven by medical cost inflation exceeding pricing power. The Piotroski F-Score of 2/9 is alarmingly low, indicating poor earnings quality and deteriorating financial position. Most troubling is the negative FCF yield of -8.6% despite reported $1.3B in free cash flow, suggesting the company is burning capital relative to valuation. The Altman Z-Score of 1.91 places Humana in the 'gray zone' for financial distress. While the low beta of 0.41 and modest leverage at 0.75x D/E provide some defensive characteristics, these pale against operational challenges. The 52-week range collapse from $315 to $170 reflects market recognition of deteriorating economics. ROE of 7% and ROCE of 4.3% are woefully inadequate for a mature business requiring continuous capital deployment. I cannot justify purchasing a business experiencing operational losses, negative cash return dynamics, and weakening competitive positioning at any price in this environment. Graham would demand a substantial margin of safety—currently absent.

Bull Case

Humana could stage a recovery if management successfully implements medical cost containment initiatives and healthcare inflation moderates. At current depressed valuations, the stock offers asymmetric upside if operational losses prove temporary and the company stabilizes margins through pricing discipline and provider relationship optimization.

Bear Case

Deteriorating fundamentals suggest losses could persist or worsen if Medicare Advantage medical loss ratios remain elevated. Further competitive pricing pressure or regulatory headwinds could force additional write-downs, potentially triggering covenant violations or dividend cuts.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer